The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Uveal melanoma: epidemiology, etiology, and treatment of primary disease
Open accessAbstract
Abstract: Uveal melanoma (UM) is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment is crucial, as survival correlates with primary tumor size. However, approximately 50% of patients will develop metastatic disease with 6–12 months’ survival from metastatic diagnosis. Genomic analyses have led to the development of gene-expression profiles that effectively predict metastatic progression; unfortunately, no adjuvant therapy has been shown to prolong survival to date. New insights into the molecular biology of UM have found frequent activating mutations in genes encoding for the G-protein α-subunit, GNAQ and GNA11 , and improved understanding of the downstream signaling pathways MAPK, PI3K/Akt, and Hippo have afforded an array of new targets for treatment of this disease. Studies are under way with rationally developed regimens targeting these pathways, and novel agents are under development. We review the diagnosis, management, and surveillance of primary UM and the adjuvant therapy trials under way. Keywords: uveal melanoma, ocular melanoma, GNAQ, GNA11 , MAP kinase, MEK
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Cobb, M. H., & Goldsmith, E. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14843 · Cited by 1,719
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Mutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Singh, A. D., Turell, M. E., & Topham, A. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.040 · Cited by 1,267
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Ma¨kitie, T., & Kivela¨, T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,045
Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 amplicon
Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C.-X., Brugge, J. S., & Haber, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605579103 · Cited by 885
Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP
Hao, Y., Chun, A., Cheung, K., Rashidi, B., & Yang, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709037200 · Cited by 786
Incidence of noncutaneous melanomas in the U.S.
McLaughlin, C. C., Wu, X., Jemal, A., Martin, H. J., Roche, L. M., & Chen, V. W. (2005) · Cancer · doi:10.1002/cncr.20866 · Cited by 739
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1639 · Cited by 621
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
Harbour, J. W., Roberson, E. D. O., Anbunathan, H., Onken, M. D., Worley, L. A., & Bowcock, A. M. (2013) · Nature Genetics · doi:10.1038/ng.2523 · Cited by 516
Incidence of uveal melanoma in the United States: 1973–1997
Singh, A. D., & Topham, A. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00078-2 · Cited by 512
Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.017 · Cited by 506
Incidence of Uveal Melanoma in Europe
Virgili, G., Gatta, G., Ciccolallo, L., Capocaccia, R., Biggeri, A., Crocetti, E., Lutz, J.-M., & Paci, E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.032 · Cited by 482
Mitogenic signaling pathways induced by G protein‐coupled receptors
Rozengurt, E. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21246 · Cited by 460
Uveal melanoma: From diagnosis to treatment and the science in between
Chattopadhyay, C., Kim, D. W., Gombos, D. S., Oba, J., Qin, Y., Williams, M. D., Esmaeli, B., Grimm, E. A., Wargo, J. A., Woodman, S. E., et al. (2016) · Cancer · doi:10.1002/cncr.29727 · Cited by 443
Metastatic disease from uveal melanoma: treatment options and future prospects
Carvajal, R. D., Schwartz, G. K., Tezel, T., Marr, B., Francis, J. H., & Nathan, P. D. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309034 · Cited by 438
Self-citationWu, D. Q., Lee, C. H., Rhee, S. G., & Simon, M. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46018-8 · Cited by 325
Variates of Survival in Metastatic Uveal Melanoma
Rietschel, P., Panageas, K. S., Hanlon, C., Patel, A., Abramson, D. H., & Chapman, P. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6534 · Cited by 316
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Moore, A. R., Ceraudo, E., Sher, J. J., Guan, Y., Shoushtari, A. N., Chang, M. T., Zhang, J. Q., Walczak, E. G., Kazmi, M. A., Taylor, B. S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3549 · Cited by 314
Collaborative Ocular Melanoma Study Group
Fine, S. L. (1999) · Archives of Family Medicine · doi:10.1001/archfami.8.1.11-a · Cited by 305
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Johansson, P., Aoude, L. G., Wadt, K., Glasson, W. J., Warrier, S. K., Hewitt, A. W., Kiilgaard, J. F., Heegaard, S., Isaacs, T., Franchina, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6614 · Cited by 303
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Field, M. G., Decatur, C. L., Kurtenbach, S., Gezgin, G., van der Velden, P. A., Jager, M. J., Kozak, K. N., & Harbour, J. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2071 · Cited by 293
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Landreville, S., Agapova, O. A., Matatall, K. A., Kneass, Z. T., Onken, M. D., Lee, R. S., Bowcock, A. M., & Harbour, J. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0946 · Cited by 289
Members of the Gq alpha subunit gene family activate phospholipase C beta isozymes.
Lee, C. H., Park, D., Wu, D., Rhee, S. G., & Simon, M. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41962-x · Cited by 281
Uveal Melanomas with SF3B1 Mutations
Yavuzyigitoglu, S., Koopmans, A. E., Verdijk, R. M., Vaarwater, J., Eussen, B., van Bodegom, A., Paridaens, D., Kiliç, E., & de Klein, A. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.023 · Cited by 267
Collaborative Ocular Melanoma Study Group (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.07.006 · Cited by 259
Sunlight Exposure as Risk Factor for Intraocular Malignant Melanoma
Tucker, M. A., Shields, J. A., Hartge, P., Augsburger, J., Hoover, R. N., & Fraumeni, J. F. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509263131305 · Cited by 251
Population-Based Incidence of Uveal Melanoma in Various Races and Ethnic Groups
Hu, D.-N., Yu, G.-P., McCormick, S. A., Schneider, S., & Finger, P. T. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.05.034 · Cited by 238
The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases
Liang, J., Wu, Y.-L., Chen, B.-J., Zhang, W., Tanaka, Y., & Sugiyama, H. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.6087 · Cited by 222
Damato, E. M., & Damato, B. E. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.01.048 · Cited by 218
Kuk, D., Shoushtari, A. N., Barker, C. A., Panageas, K. S., Munhoz, R. R., Momtaz, P., Ariyan, C. E., Brady, M. S., Coit, D. G., Bogatch, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0522 · Cited by 201
Self-citationIntermittent and Chronic Ultraviolet Light Exposure and Uveal Melanoma
Shah, C. P., Weis, E., Lajous, M., Shields, J. A., & Shields, C. L. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.04.020 · Cited by 190
Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.
Kalinec, G., Nazarali, A. J., Hermouet, S., Xu, N., & Gutkind, J. S. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.10.4687 · Cited by 161
Quality of Life After Iodine 125 Brachytherapy vs Enucleation for Choroidal Melanoma
Collaborative Ocular Melanoma Study–Quality of Life Study Group (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.2.226 · Cited by 150
Khalili, J. S., Yu, X., Wang, J., Hayes, B. C., Davies, M. A., Lizee, G. A., Esmaeli, B., & Woodman, S. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3227 · Cited by 147
Risk Factors for Ocular Melanoma: Western Canada Melanoma Study 2 3
Gallagher, R. P., Elwood, M., Rootman, J., Spinelli, J. J., Hill, G. B., Threlfall, W. J., & Birdsell, J. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/74.4.775 · Cited by 138
GNAQ and GNA11 mutations in uveal melanoma
Shoushtari, A. N., & Carvajal, R. D. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000121 · Cited by 131
Self-citationBabchia, N., Calipel, A., Mouriaux, F., Faussat, A., & Mascarelli, F. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3974 · Cited by 128
Epigenetics, MicroRNAs, and Carcinogenesis: Functional Role of MicroRNA-137 in Uveal Melanoma
Chen, X., Wang, J., Shen, H., Lü, J., Li, C., Hu, D., Dong, X. D., Yan, D., & Tu, L. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5272 · Cited by 126
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Milman, T. (2011) · Yearbook of Ophthalmology · doi:10.1016/j.yoph.2011.03.038 · Cited by 124
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Surriga, O., Rajasekhar, V. K., Ambrosini, G., Dogan, Y., Huang, R., & Schwartz, G. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0499 · Cited by 118
Digital PCR Validates 8q Dosage as Prognostic Tool in Uveal Melanoma
Versluis, M., de Lange, M. J., van Pelt, S. I., Ruivenkamp, C. A. L., Kroes, W. G. M., Cao, J., Jager, M. J., Luyten, G. P. M., & van der Velden, P. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116371 · Cited by 108
Eldh, M., Bagge, R. O., Lässer, C., Svanvik, J., Sjöstrand, M., Mattsson, J., Lindnér, P., Choi, D., Gho, Y. S., & Lötvall, J. O. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-962 · Cited by 105
NCCN Guidelines Insights: Melanoma, Version 3.2016
Coit, D. G., Thompson, J. A., Algazi, A. P., Andtbacka, R. H. I., Bichakjian, C. K., Carson, W. E., Daniels, G. A., DiMaio, D. J., Fields, R. C., Fleming, M. D., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0101 · Cited by 102
Genomic Profile of 320 Uveal Melanoma Cases: Chromosome 8p-Loss and Metastatic Outcome
Ewens, K. G., Kanetsky, P. A., Richards‐Yutz, J., Al-Dahmash, S. A., Luca, M. C. D., Bianciotto, C. G., Shields, C. L., & Ganguly, A. A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12195 · Cited by 101
Chen, X., He, D., Dong, X. D., Dong, F., Wang, J., Wang, L., Tang, J., Hu, D., Yan, D., & Tu, L. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10977 · Cited by 89
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 84
Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
Ho, A. L., Musi, E., Ambrosini, G., Nair, J. S., Vasudeva, S. D., de Stanchina, E., & Schwartz, G. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040439 · Cited by 83
Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K., & Hassan, N. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1525-z · Cited by 81
Park, S. J., Oh, C., Kim, B., Woo, S. J., Cho, H., & Park, K. H. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16532 · Cited by 79
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
Pópulo, H., Soares, P., Rocha, A. S., Silva, P., & Lopes, J. M. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32832ccd09 · Cited by 79
Kivelä, T., Puusaari, I., & Damato, B. E. (2003) · Ophthalmology · doi:10.1016/j.ophtha.2003.02.001 · Cited by 63
MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.
Dong, F., & Lou, D. (2012) · PubMed Central · Cited by 62
Venza, M., Visalli, M., Catalano, T., Biondo, C., Beninati, C., Teti, D. V., & Venza, I. (2016) · Oncology Reports · doi:10.3892/or.2016.4618 · Cited by 55
de Lange, M. J., Razzaq, L., Versluis, M., Verlinde, S., Doğrusöz, M., Böhringer, S., Marinkovic, M., Luyten, G. P. M., de Keizer, R. J. W., de Gruijl, F. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138002 · Cited by 48
Human papillomavirus capsids preferentially bind and infect tumor cells
Kines, R. C., Cerio, R. J., Roberts, J. N., Thompson, C. D., Pinos, E. D. L., Lowy, D. R., & Schiller, J. T. (2015) · International Journal of Cancer · doi:10.1002/ijc.29823 · Cited by 47
Puusaari, I., Damato, B. E., & Kivelä, T. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0461-9 · Cited by 47
The biology and management of uveal melanoma
Sato, T., Han, F., & Yamamoto, A. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0066-z · Cited by 40
Expression of Angiogenic Factors Cyr61 and Tissue Factor in Uveal Melanoma
Walker, T. M. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.12.1719 · Cited by 39
Guan, X., Wang, H., Ma, F., Qian, H., Yi, Z., & Xu, B. (2016) · Medicine · doi:10.1097/md.0000000000003134 · Cited by 14
Orchestrating epigenetic roles targeting ocular tumors
Zhang, H., Wen, X., Lu, L., & Fan, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s93995 · Cited by 5
Cited by
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets
Chen, X., Shi, C., He, M., Xiong, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01570-w · Cited by 1,007
Metadata
- Authors
- Krantz, B. A., Dave, N., Komatsubara, K. M., Marr, B. P., & Carvajal, R. D.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2017-01
- Volume
- Volume 11
- Pages
- 279-289
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W2583872728
- Cited by
- 402
- References
- 68
- FWCI
- 27.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.